CN100337626C - 酰化的、杂芳基－稠合的环烯基胺和它们作为药物的用途 - Google Patents

酰化的、杂芳基－稠合的环烯基胺和它们作为药物的用途 Download PDF

Info

Publication number
CN100337626C
CN100337626C CNB038191253A CN03819125A CN100337626C CN 100337626 C CN100337626 C CN 100337626C CN B038191253 A CNB038191253 A CN B038191253A CN 03819125 A CN03819125 A CN 03819125A CN 100337626 C CN100337626 C CN 100337626C
Authority
CN
China
Prior art keywords
alkyl
phenyl
substituents
heteroaryl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038191253A
Other languages
English (en)
Chinese (zh)
Other versions
CN1674895A (zh
Inventor
H·斯特罗贝尔
P·沃尔法特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of CN1674895A publication Critical patent/CN1674895A/zh
Application granted granted Critical
Publication of CN100337626C publication Critical patent/CN100337626C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
CNB038191253A 2002-08-07 2003-07-24 酰化的、杂芳基－稠合的环烯基胺和它们作为药物的用途 Expired - Fee Related CN100337626C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02017586.5 2002-08-07
EP02017586A EP1388342A1 (en) 2002-08-07 2002-08-07 Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals

Publications (2)

Publication Number Publication Date
CN1674895A CN1674895A (zh) 2005-09-28
CN100337626C true CN100337626C (zh) 2007-09-19

Family

ID=30129194

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038191253A Expired - Fee Related CN100337626C (zh) 2002-08-07 2003-07-24 酰化的、杂芳基－稠合的环烯基胺和它们作为药物的用途

Country Status (26)

Country Link
EP (2) EP1388342A1 (enExample)
JP (1) JP4608315B2 (enExample)
KR (1) KR101061727B1 (enExample)
CN (1) CN100337626C (enExample)
AR (1) AR040790A1 (enExample)
AT (1) ATE524178T1 (enExample)
AU (1) AU2003251466B2 (enExample)
BR (1) BR0313240A (enExample)
CA (1) CA2494302C (enExample)
DK (1) DK1534277T3 (enExample)
ES (1) ES2373651T3 (enExample)
HR (1) HRP20050119A2 (enExample)
IL (1) IL166494A (enExample)
MA (1) MA27331A1 (enExample)
ME (1) MEP25808A (enExample)
MX (1) MXPA05000833A (enExample)
MY (1) MY140840A (enExample)
NO (1) NO330011B1 (enExample)
NZ (1) NZ538090A (enExample)
PL (1) PL212119B1 (enExample)
PT (1) PT1534277E (enExample)
RS (1) RS52385B (enExample)
RU (1) RU2338743C2 (enExample)
TW (1) TWI328582B (enExample)
WO (1) WO2004014372A1 (enExample)
ZA (1) ZA200410274B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108602760A (zh) * 2016-01-25 2018-09-28 武田药品工业株式会社 茚烷衍生物作为mglur7调节剂

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004042607A1 (de) 2004-09-03 2006-03-09 Bayer Healthcare Ag Substituierte Phenylaminothiazole und ihre Verwendung
EP1741708A1 (en) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals
EP1741709A1 (en) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
DE102006042143A1 (de) 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
EP1905764A1 (en) * 2006-09-30 2008-04-02 Sanofi-Aventis Substituted 2-Phenyl-benzimidazoles and their use as pharmaceuticals
EP1923062A1 (en) 2006-11-16 2008-05-21 sanofi-aventis Imidazo[2,1-b]thiazoles and their use as pharmaceuticals
DE102006056739A1 (de) 2006-12-01 2008-06-05 Bayer Healthcare Ag Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
DE102006056740A1 (de) 2006-12-01 2008-06-05 Bayer Healthcare Ag Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
EP1939181A1 (en) 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
EP1964841A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]azine and their use as pharmaceuticals
EP1964840A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]pyridines and their use as pharmaceuticals
DE102007035367A1 (de) 2007-07-27 2009-01-29 Bayer Healthcare Ag Substituierte Aryloxazole und ihre Verwendung
DE102007036076A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
DE102007061764A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Anellierte Cyanopyridine und ihre Verwendung
DE102007061763A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte azabicyclische Verbindungen und ihre Verwendung
DE102008013587A1 (de) 2008-03-11 2009-09-17 Bayer Schering Pharma Aktiengesellschaft Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
US8791146B2 (en) 2008-05-29 2014-07-29 Bayer Intellectual Property Gmbh 2-alkoxy-substituted dicyanopyridines and their use
AU2009289846B2 (en) * 2008-09-02 2014-10-16 Sanofi-Aventis Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof
DE102008062567A1 (de) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Dipeptoid-Prodrugs und ihre Verwendung
CN101759683B (zh) * 2008-12-25 2011-12-28 哈尔滨誉衡药业股份有限公司 二氢化茚酰胺化合物制备方法、包含其的药物组合物、及其作为蛋白激酶抑制剂的应用
DE102009006602A1 (de) 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
DE102010030688A1 (de) 2010-06-30 2012-01-05 Bayer Schering Pharma Aktiengesellschaft Substituierte Dicyanopyridine und ihre Verwendung
US20120058983A1 (en) 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
RU2545758C1 (ru) * 2014-03-20 2015-04-10 Общество с ограниченной ответственностью "Алион" Бициклические пиримидины или их фармацевтически приемлемые соли-активаторы антиоксидантной программы и их применение в качестве цитопротекторов
KR102633122B1 (ko) 2014-08-01 2024-02-05 누에볼루션 에이/에스 브로모도메인에 대하여 활성을 갖는 화합물
CN111108105B (zh) 2017-09-22 2023-03-31 朱比兰特埃皮帕德有限公司 作为pad抑制剂的杂环化合物
KR102782563B1 (ko) 2017-10-18 2025-03-14 주빌런트 에피파드 엘엘씨 Pad 억제제로서의 이미다조-피리딘 화합물
AU2018362046B2 (en) 2017-11-06 2023-04-13 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
HUE067265T2 (hu) 2017-11-24 2024-10-28 Jubilant Episcribe Llc Heterociklusos vegyületek mint PRMT5 inhibitorok
EP3765453A1 (en) 2018-03-13 2021-01-20 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
WO2025097104A1 (en) * 2023-11-02 2025-05-08 Pgi Drug Discovery Llc Thienyl compounds for the treatment of a central nervous system disease or disorder

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1072263A1 (en) * 1998-03-26 2001-01-31 Japan Tobacco Inc. Amide derivatives and nociceptin antagonists
WO2001068652A1 (en) * 2000-03-17 2001-09-20 Novo Nordisk A/S Condensed imidazoles as histamine h3 receptor ligands

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08325234A (ja) * 1995-05-30 1996-12-10 Yamanouchi Pharmaceut Co Ltd 安息香酸誘導体又はその塩
JP3013989B2 (ja) * 1998-03-26 2000-02-28 日本たばこ産業株式会社 アミド誘導体及びノシセプチンアンタゴニスト
TWI241190B (en) * 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
MY136316A (en) * 2001-02-13 2008-09-30 Sanofi Aventis Deutschland Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical.
PE20020856A1 (es) * 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-tetrahidronaftil aminas aciladas

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1072263A1 (en) * 1998-03-26 2001-01-31 Japan Tobacco Inc. Amide derivatives and nociceptin antagonists
WO2001068652A1 (en) * 2000-03-17 2001-09-20 Novo Nordisk A/S Condensed imidazoles as histamine h3 receptor ligands

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108602760A (zh) * 2016-01-25 2018-09-28 武田药品工业株式会社 茚烷衍生物作为mglur7调节剂

Also Published As

Publication number Publication date
MA27331A1 (fr) 2005-05-02
IL166494A (en) 2011-12-29
PL373279A1 (en) 2005-08-22
MXPA05000833A (es) 2005-04-19
MY140840A (en) 2010-01-29
CN1674895A (zh) 2005-09-28
AR040790A1 (es) 2005-04-20
KR101061727B1 (ko) 2011-09-05
TW200412949A (en) 2004-08-01
ZA200410274B (en) 2006-07-26
NO20050830L (no) 2005-02-16
IL166494A0 (en) 2006-01-15
JP4608315B2 (ja) 2011-01-12
HK1079427A1 (en) 2006-04-07
TWI328582B (en) 2010-08-11
DK1534277T3 (da) 2012-01-09
MEP25808A (en) 2010-06-10
CA2494302C (en) 2011-11-29
ES2373651T3 (es) 2012-02-07
CA2494302A1 (en) 2004-02-19
BR0313240A (pt) 2005-09-27
RU2338743C2 (ru) 2008-11-20
RU2005106292A (ru) 2005-09-10
PL212119B1 (pl) 2012-08-31
EP1534277B1 (en) 2011-09-14
PT1534277E (pt) 2011-12-06
HRP20050119A2 (en) 2006-05-31
AU2003251466B2 (en) 2009-04-23
ATE524178T1 (de) 2011-09-15
NZ538090A (en) 2007-02-23
NO330011B1 (no) 2011-02-07
EP1388342A1 (en) 2004-02-11
RS52385B (sr) 2013-02-28
JP2005538124A (ja) 2005-12-15
RS20050097A (sr) 2007-06-04
KR20050059056A (ko) 2005-06-17
AU2003251466A1 (en) 2004-02-25
EP1534277A1 (en) 2005-06-01
WO2004014372A1 (en) 2004-02-19

Similar Documents

Publication Publication Date Title
CN100337626C (zh) 酰化的、杂芳基－稠合的环烯基胺和它们作为药物的用途
CN1296346C (zh) 酰化的6,7,8,9－四氢－5h－苯并环庚烯基胺和它们作为药物的用途
CN1259307C (zh) 酰化的二氢化茚基胺及其作为药物的用途
CN1107061C (zh) 趋化细胞因子受体－3拮抗剂
CN1221529C (zh) 取代的n－[(氨基亚氨基甲基或氨甲基)苯基]丙基酰胺
CN1151136C (zh) 缩合哒嗪系化合物
CN1304365C (zh) 酰化的芳基环烷基胺和它们作为药物的用途
CN1142161C (zh) 作为5－ht4受体拮抗剂的二氢苯并二噁烯羧酰胺与酮衍生物
CN1163484C (zh) 4-芳酰基-哌啶-ccr-3受体拮抗剂ⅲ
CN1191249C (zh) 用于治疗、特别是治疗良性前列腺增生的喹啉和喹唑啉化合物
CN1468216A (zh) 含氮五员环化合物
CN1856467A (zh) 用作嗜中性白细胞弹性蛋白酶抑制剂的2－吡啶酮衍生物及其用途
CN1741999A (zh) 用作GSK－3β抑制剂的哒嗪酮衍生物
CN1662524A (zh) 用作组胺h3拮抗剂的吲哚衍生物
CN1694879A (zh) 具有激酶抑制活性的异喹啉衍生物和包含异喹啉衍生物的药剂
CN1474810A (zh) 取代脲,神经肽yy5受体拮抗剂
HK1048306A1 (en) Pharmaceutically active sulfonamide derivatives
CN1701068A (zh) 新颖的化合物和它们的用途
CN1751044A (zh) 用作pepck抑制剂的磺酰胺取代的黄嘌呤
CN1224624C (zh) 1,8－二氮杂萘－2(1h)－酮衍生物
CN1856477A (zh) 异喹啉钾通道抑制剂
CN1658877A (zh) 碱性非肽缓激肽拮抗剂及其药物组合物
CN1471520A (zh) 氨基烷氧基苯甲酰基-苯并呋喃类或苯并噻吩类,它们的制备方法以及含有它们的组合物
CN1856472A (zh) 异喹啉酮钾通道抑制剂
CN1993358A (zh) 作为趋化因子受体拮抗剂的噻唑衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1079427

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1079427

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070919

Termination date: 20130724